棘孢小单孢菌耐受无机磷突变株129－P1产生的新的氨基糖苷抗生素复合物GP

ANTIBIOTIC GP, A NEW AMINOGLYCOSIDE ANTIBIOTIC COMPLEX PRODUCED BY MICROMONOSPORA ECHINOSPORA MUTANT 129-P1,WHICH CAN TOLERATE HIGHER CONCENTRATIONS OF PHOSPHATE

庆大霉素生产菌棘状小单孢菌耐受无机磷突变株Ｍ，ｅｃｈｉｎｏｓｐｏｒａＭｕｔａｎｔ１２９－Ｐ１产生一种新的氨基糖苷抗生素复合物ＧＰ，经分离纯化获两个单组分ＧＰＡ和ＧＰＢ。研究结果证明抗生素ＧＰＢ与紫色小单孢菌突变株Ｍ．ＰｕｒｐｕｒｅａＪＩ２０所产生的抗生素ＪＩ－２０日同质，抗生素ＧＰＡ与相模湾小单孢菌突变株Ｍ．ｓａｇａｍｉｅｎｓｉｓＮＲＲＬ１１００６０／３１生物转化的产物抗生素ＴＰＪ－Ｂ同质。抗生物ＧＰＡ和ＧＰＢ的抗菌谱广，除对绿脓假单孢菌外，均具有与庆大霉素相近的抗革兰氏阳性和阴性细菌的生物活性。对小鼠的急性毒性比庆大霉素低，体内治疗效果明显比庆大霉素好。ＧＰＡ和ＧＰＢ有协同抗细菌作用。

Antibiotic GP,a new aminoglycoside antibiotic complex produced by Micromonospora echfnospora mutant 129-p1,which can tolera-te higher conentrations of phospliate was studied,This complex can be separated into two components, antibiotic GPA and antibiotic GPB,The results of the physico-chemical and biological properties showed that antibiotic GPB was identical to antibiotic JI-20B produced by Micromo-nora purpurea JI-20,and antibiotic GPA was identical to anti biotic TPJ-B which produced by means of microbial transformtion of antibiotic JI-20B resulted from Micromonospora sagamiensis NRRL-10060/31.The antibacterial activities of antibiotic GPA and GPB appear to be similar to that of Gentamicin ezcept for against Pseudomonas aeruginosa.The toxicity tests in mice showed that the toxicity of antibiotic GPA and GPB were lower than that of Gentamicin and the protection tests in vivo in mice indicated that the activities of antibiotic GPA and GPB in vivo were more potent than that of Gentamicin. The synergism between anti-biotic GPA and GPB against bacteria can be seen in vitro and in vivo